Randy’s perspective: Living with Parkinson’s on his terms

Image of Randy, real CREXONT patient.

For Randy, curiosity and critical thinking have been at the center of his life’s journey, from navigating early education challenges to pioneering materials science innovations, and eventually, to managing life with Parkinson’s disease. His story is one of understanding, perseverance, and finding clarity in the face of life-altering change.

Born and raised in New York City, Randy’s early years were shaped by both challenge and promise. At age eight, he was sent to a special school because he struggled with reading, though his talent for math was quickly recognized. “They said I was bright, just uninterested in reading,” Randy recalls. “They taught me how to think, not just memorize facts, but how to analyze and break things down. That mindset shaped everything.”
 
Early on, Randy moved to New Jersey, where he would later meet his future wife through a country club. In a twist of fate, he initially hesitated to ask her out, mistakenly believing she was married, only to learn it was actually her twin sister! Their relationship blossomed over frequent weekend trips into NYC, where they shared meals and memories. “She eventually asked if I was ever going to propose, so I did.”

 

In 1999, Randy began working with a compound that would shape the next 25 years of his life. He stabilized it and found ways to integrate it into garments and insulation, even developing a vacuum-sealed foam with buoyancy, which is useful for everything from clothing to battery protection to home construction. Despite some setbacks, his passion never wavered. “I decided the way to move forward is to constantly create something new.”

 

That same drive helped him face Parkinson’s disease when he was diagnosed in 2017, at age 69. One afternoon during a lunch break with a friend, he began experiencing unexpected symptoms. His friend brought him to a hospital, where overnight testing led to a possible diagnosis. When he called a neurologist’s office for confirmation, his sister-in-law reminded him that her son, Dr Falconer, was a specialist in Parkinson’s. Randy was seen the next day.

“The diagnosis was a shock. But looking back, I should’ve seen the signs, like when I started to struggle with rock climbing.”

Dr Falconer became Randy’s go-to expert and care partner from that point on. Their relationship, both family and professional, became a trusted foundation as they worked together to find the right treatment plan. “I’ve had other neurologists before, people who didn’t even catch my diagnosis, but Dr Falconer took the time to listen and really understand what I was going through.”

 

Working with Dr Falconer, Randy began exploring treatment options. His initial experiences weren’t easy. In fact, some approaches didn’t sit well with him, but over time, he and his doctor found a path forward. Today, Randy takes CREXONT® (carbidopa and levodopa) extended-release capsules three times daily. “We tried different timing. After about 10 hours, I’d start noticing symptoms again. Now, there’s roughly seven hours between doses, and it’s working well for me.”

Randy is thoughtful and analytical about his condition. “It doesn’t matter what I’m dealing with, I always take an analytical approach. That’s how I think, and it’s how I manage my Parkinson’s.”

Living with Parkinson’s has changed his day-to-day routine significantly. Simple tasks, like getting dressed, now take much longer. He’s cautious on the stairs, aware of his balance and gait. He’s also noticed that everything moves slowly, cooking, moving, thinking. But he hasn’t let that stop him. “You’re painfully aware of it every day. But my attitude is, I’m going to win this battle. I may not in reality, but I think I am.”

 

Randy still climbs rock walls, although less frequently, and plays pickleball with neighbors. He also treasures time with his family. His daughter, a nurse and healthcare leader, and his son, a web developer, both live nearby with their children. He sees his daughter’s family weekly for Sunday dinners, and visits his son’s family every couple of months. His grandchildren are the joy of his life, from his granddaughter’s incredible drawing talent to his youngest grandson’s boundless energy. “He’s happiest when someone’s chasing him around the house,” Randy laughs.

In 2020, Randy made another major change. He sold his Tudor-style home in New Jersey and moved into a modern home in a 55+ community to be closer to his daughter and to simplify his lifestyle during the pandemic. “It was the right time. The community here is amazing; people genuinely look out for one another. It makes a huge difference.”

Randy also finds purpose in helping others with Parkinson’s in his community. People often approach him for advice. “People see that I’m doing well and ask what I’m taking, what I’m doing. I always tell them: I’m not a doctor but talk to your physician about what’s available.”

“I do tell them what’s helped me, and I always say, ‘Dr Falconer is the one who got me here.’”

 

He’s also passionate about staying informed and continues to read extensively about Parkinson’s. “There’s a lot of information out there, and not all of it is worthwhile. But I always ask Dr Falconer what’s new. When he suggested trying CREXONT, I trusted him, even though it was new.”

 

When asked why he’s sharing his story, Randy doesn’t hesitate: “People need to know there’s hope. There are new things coming out that can help people live better. The community needs to be enlightened. I want people to know they have options—and that things can get better.”

 

Randy’s experience with CREXONT is his own and may not reflect the experience of every patient. For some patients, CREXONT may cause falling asleep during daily activities. Side effects may include nausea and anxiety. Individual results will vary. Talk to your patients to see if CREXONT is right for them. Only an HCP should assess each patient’s condition and advise them on treatment options.


IMPORTANT SAFETY INFORMATION

Indications and Usage

CREXONT® (carbidopa and levodopa) extended-release capsules for oral use is indicated for the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication in adults.

Dosage and Administration

  • Levodopa-naïve patients: Starting dose is 35 mg carbidopa/140 mg levodopa taken orally twice daily for the first three days; thereafter, dosage may be increased gradually as needed
  • For patients converting to CREXONT from immediate-release carbidopa/levodopa, dosages are not substitutable on a 1:1 basis. See full prescribing information Section 2.2 for instructions
  • For patients converting from Rytary® (carbidopa and levodopa) extended-release capsules, initiate CREXONT on an approximately 1:1 mg basis using the levodopa component for conversion
  • CREXONT may be taken up to four times daily. The maximum recommended daily dosage is 525 mg carbidopa/2100 mg levodopa
  • CREXONT may be taken with or without food. Capsules should not be chewed, divided or crushed
  • CREXONT should not be taken with alcohol

Contraindications

Nonselective MAO inhibitors.

Warnings and Precautions

  • CREXONT may cause falling asleep during activities of daily living, somnolence or dizziness. Patients should avoid activities that require alertness such as driving and operating machinery until they know how CREXONT affects them
  • It is important to avoid sudden discontinuation or rapid dose reduction to reduce the risk of withdrawal symptoms such as high fever or confusion. Patients who are discontinuing CREXONT should taper off with healthcare provider guidance
  • Consider dose reductions or stopping CREXONT in patients with hallucinations or impulse control disorders (e.g., gambling, sexual urges, or uncontrolled spending)
  • Consider dose reduction in patients with dyskinesia
  • Patients with a major psychotic disorder should not be treated with CREXONT
  • Monitor patients with a history of cardiovascular disease for cardiac function
  • Monitor patients with a history of peptic ulcer for upper GI hemorrhage
  • Monitor patients with glaucoma for increased intraocular pressure

Adverse Reactions

The most common adverse reactions (incidence ≥ 3% and greater than immediate-release CD/LD) are nausea and anxiety.

Drug Interactions

Iron salts and dopamine D2 antagonists, including metoclopramide, may reduce the effectiveness of CREXONT.

Use in Specific Populations

Pregnancy: Based on animal data, CREXONT may cause fetal harm. There are no adequate data on the developmental risk associated with the use of CREXONT in pregnant women.
Breastfeeding: The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for CREXONT.
Geriatric patients: There were no differences in safety outcomes between patients less than 65 years of age, 65-75 years of age, or 75 years and older.

To report SUSPECTED ADVERSE REACTIONS, contact Amneal Specialty, a division of Amneal Pharmaceuticals, LLC at 1‑877‑835‑5472 or the FDA at 1‑800‑FDA‑1088 or www.fda.gov/medwatch.

Please see full Prescribing Information for CREXONT.

Content is for guidance only. Please use clinical judgment when prescribing CREXONT. Dosage is individualized for each patient.